Ypsomed Holding AG Stock

Equities

YPSN

CH0019396990

Medical Equipment, Supplies & Distribution

Market Closed - Swiss Exchange 11:30:38 2024-04-18 am EDT 5-day change 1st Jan Change
380 CHF +2.15% Intraday chart for Ypsomed Holding AG +2.43% +25.41%
Sales 2024 * 558M 612M Sales 2025 * 665M 729M Capitalization 5.08B 5.57B
Net income 2024 * 77M 84.47M Net income 2025 * 118M 129M EV / Sales 2024 * 9.49 x
Net Debt 2024 * 214M 235M Net Debt 2025 * 252M 276M EV / Sales 2025 * 8.02 x
P/E ratio 2024 *
66.1 x
P/E ratio 2025 *
42.9 x
Employees 2,200
Yield 2024 *
0.52%
Yield 2025 *
0.79%
Free-Float 26.09%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.75%
1 week+1.33%
Current month+5.41%
1 month+7.50%
3 months+27.95%
6 months+51.70%
Current year+25.41%
More quotes
1 week
364.50
Extreme 364.5
389.50
1 month
340.50
Extreme 340.5
389.50
Current year
287.50
Extreme 287.5
389.50
1 year
195.20
Extreme 195.2
389.50
3 years
121.60
Extreme 121.6
389.50
5 years
102.40
Extreme 102.4
389.50
10 years
76.10
Extreme 76.1
389.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 06-09-30
Chief Operating Officer 60 15-09-30
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 63 17-12-31
Director/Board Member 54 18-12-31
Chairman 60 20-06-30
More insiders
Date Price Change Volume
24-04-18 380 +2.15% 16,283
24-04-17 372 -3.00% 8,923
24-04-16 383.5 -1.03% 16,574
24-04-15 387.5 +1.97% 13,227
24-04-12 380 +1.33% 12,801

Delayed Quote Swiss Exchange, April 18, 2024 at 11:30 am EDT

More quotes
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
372 CHF
Average target price
365 CHF
Spread / Average Target
-1.88%
Consensus